Literature DB >> 9632398

Hormone replacement therapy again. Risk-benefit relation differs between populations and individuals.

K T Khaw.   

Abstract

Mesh：

Year:  1998        PMID： 9632398      PMCID： PMC1113355          DOI： 10.1136/bmj.316.7148.1842

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  26 in total

Review 1.  Hormone replacement therapy and cardiovascular disease.

Authors:  T W Meade; A Berra
Journal:  Br Med Bull       Date:  1992-04       Impact factor: 4.291

2.  Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials.

Authors:  E Hemminki; K McPherson
Journal:  BMJ       Date:  1997-07-19

3.  Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women.

Authors:  S A Beresford; N S Weiss; L F Voigt; B McKnight
Journal:  Lancet       Date:  1997-02-15       Impact factor: 79.321

4.  Hormone replacement therapy for all? Universal prescription is desirable.

Authors:  P Toozs-Hobson; L Cardozo
Journal:  BMJ       Date:  1996-08-10

5.  Postmenopausal hormone therapy and mortality.

Authors:  F Grodstein; M J Stampfer; G A Colditz; W C Willett; J E Manson; M Joffe; B Rosner; C Fuchs; S E Hankinson; D J Hunter; C H Hennekens; F E Speizer
Journal:  N Engl J Med       Date:  1997-06-19       Impact factor: 91.245

Review 6.  The primary prevention of coronary heart disease in women.

Authors:  J W Rich-Edwards; J E Manson; C H Hennekens; J E Buring
Journal:  N Engl J Med       Date:  1995-06-29       Impact factor: 91.245

7.  Postmenopausal estrogen and progestin use and the risk of cardiovascular disease.

Authors:  F Grodstein; M J Stampfer; J E Manson; G A Colditz; W C Willett; B Rosner; F E Speizer; C H Hennekens
Journal:  N Engl J Med       Date:  1996-08-15       Impact factor: 91.245

8.  Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease.

Authors:  M X Tang; D Jacobs; Y Stern; K Marder; P Schofield; B Gurland; H Andrews; R Mayeux
Journal:  Lancet       Date:  1996-08-17       Impact factor: 79.321

9.  The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

Authors:  G A Colditz; S E Hankinson; D J Hunter; W C Willett; J E Manson; M J Stampfer; C Hennekens; B Rosner; F E Speizer
Journal:  N Engl J Med       Date:  1995-06-15       Impact factor: 91.245

10.  Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group.

Authors:  K Michaëlsson; J A Baron; B Y Farahmand; O Johnell; C Magnusson; P G Persson; I Persson; S Ljunghall
Journal:  BMJ       Date:  1998-06-20
View more
  4 in total

1.  Risk-benefit analysis: from a logical point of view.

Authors:  Georg Spielthenner
Journal:  J Bioeth Inq       Date:  2012-03-21       Impact factor: 1.352

Review 2.  Preventing fractures in postmenopausal women with osteoporosis. A review of recent controlled trials of antiresorptive agents.

Authors:  M Hochberg
Journal:  Drugs Aging       Date:  2000-10       Impact factor: 3.923

3.  A case-control study on the effect of hormone replacement therapy on ischaemic heart disease.

Authors:  Julia Hippisley-Cox; Mike Pringle; Nicola Crown; Carol Coupland
Journal:  Br J Gen Pract       Date:  2003-03       Impact factor: 5.386

4.  Predictors of first hip fracture and mortality post fracture in older women.

Authors:  P Fitzpatrick; P N Kirke; L Daly; I Van Rooij; E Dinn; H Burke; J Heneghan; G Bourke; J Masterson
Journal:  Ir J Med Sci       Date:  2001 Jan-Mar       Impact factor: 2.089
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.